[Edaily Reporter Shin Ha-yeon ] SyntekaBio,Inc.(226330)hit its daily price limit early in the trading session.
According to MP Doctor on the 10th, as of 9:10 a.m. that day, SyntekaBio,Inc. was trading at 1,872 won, up 30.0% (432 won) from the previous trading day.
This is believed to be due to the company’s announcement after the market closed the previous day that it had signed a contract worth 6.48 billion won, which boosted investor sentiment.
This is a colocation supply contract with Ato Research—a company specializing in GPUaaS and GPU token services based on domestic data center operations—to host high-performance AI infrastructure that will be expanded in phases up to a maximum of 2 MW (2,000 kW). The contract period is 1,095 days, running from November 1 of this year through October 31, 2029. The value of this supply contract amounts to 188.96% of the company’s recent revenue.
Through this long-term supply agreement, the two companies have established a solid foundation for collaboration to lead the global services market and plan to continuously enhance their infrastructure cooperation in line with growing global demand.
SyntekaBio,Inc. stated that, with this agreement, its supply system—which enables the integration of high-performance AI services within the same data center—has now fully come online. Accordingly, SyntekaBio,Inc. explained that it expects synergies as it will be able to integrate and utilize high-performance AI infrastructure, to be expanded as needed in the future, within its STB CLOUD service environment to further advance its innovative Agentic AI drug discovery platform (including DeepMatcher™). In addition, the two companies plan to explore ways to maximize the utilization of their respective areas of expertise—platforms and infrastructure.
Jeong Jong-seon, CEO of SyntekaBio,Inc., stated, “This achievement is a triumph demonstrating that the ABS Center’s eco-friendly and highly efficient infrastructure has proven its top-tier competitiveness on both domestic and international stages, within an AI paradigm where securing high power capacity and cooling efficiency are critical to success,” he said. “We will establish a stable revenue structure through our colocation business while further accelerating the global expansion of our AI new drug platform pipeline, driven by the synergies from infrastructure collaborations that we will explore from various angles in the future.”